Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group-Reference-Cited by-同舟云学术

Phase 1 Trial of Adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) Study Group

Published:2010-01 Issue:1 Volume:55 Page:50-60
ISSN:0272-6386
Container-title:American Journal of Kidney Diseases
language:en
Short-container-title:American Journal of Kidney Diseases

Author:

Joy Melanie S.,Gipson Debbie S.,Powell Leslie,MacHardy Jacqueline,Jennette J. Charles,Vento Suzanne,Pan Cynthia,Savin Virginia,Eddy Allison,Fogo Agnes B.,Kopp Jeffrey B.,Cattran Daniel,Trachtman Howard

Publisher

Elsevier BV

Subject

Nephrology

Reference34 articles.

1. Quality appraisal of clinical practice guidelines and consensus statements on the use of biologic agents in rheumatoid arthritis: a systemic review;Lopez-Olivo;Arthritis Rheum,2008

2. Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel disease;Shah;Rev Gastroenterol Disord,2008

3. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis;Lovell;N Engl J Med,2008

4. Many cytokines are very useful therapeutic targets in disease;Felderman;J Clin Invest,2008

5. A tumor necrosis factor-α-mediated pathway promoting autosomal dominant polycystic kidney disease;Li;Nat Med,2008

Cited by 70 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Podocyte-targeted therapies — progress and future directions;Nature Reviews Nephrology;2024-05-09

2. Low serum concentrations of bevacizumab and nivolumab owing to excessive urinary loss in patients with proteinuria: a case series;Cancer Chemotherapy and Pharmacology;2024-03-08

3. Ferroptosis-related genes, a novel therapeutic target for focal segmental glomerulosclerosis;BMC Nephrology;2024-02-17

4. Rationale and design of the Nephrotic Syndrome Study Network (NEPTUNE) Match in glomerular diseases: designing the right trial for the right patient, today;Kidney International;2024-02

5. Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis;Frontiers in Immunology;2023-09-19